{"_id":"token-121597","name":"Finspot Token (FIN, first issue)","ticker":"RS-FIN","pillar":"Fixed Income","type":"Tokenized Factoring Portfolio","category":"Private Credit","description":"Token on a factoring portfolio. Holders earn fixed interest only while the tokens are locked into one of Finspot's investment indices; Finspot buys tokens back at nominal value. White paper approved by the Securities Commission of Serbia on 2022-05-26 under the Law on Digital Assets. RSD 1,000 per token; RSD 35,250,000 (35,250 FIN). The issuer states that all tokens were sold in under a month; its second white paper migrates FIN into FIN2.","apy":"7–10% fixed while locked in an index (issuer)","risk":"Not rated (imported)","minInvestment":"RSD 10,000","issuer":"Finspot d.o.o. Beograd","yieldSource":null,"maturity":null,"term":null,"liquidity":"Sold directly by the issuer; no exchange listing stated","aum":"RSD 35,250,000 (35,250 FIN)","network":"Polygon","country":"Serbia","custody":null,"howToBuy":"From the issuer, through a digital-asset service provider licensed in Serbia","rating":null,"kyc":"Required (issuer offering)","networkFee":null,"networkFeeUsd":null,"investUrl":null,"source":"https://finspot.com/wp-content/uploads/2024/03/Finspot-FIN-3-Beli-Papir.pdf","lastVerified":"2026-10-16T12:00:00.000Z","featured":false,"apyPct":null,"apyPctLow":7,"apyPctHigh":10,"apyKind":"fixed","minInvestmentUsd":null,"custodyType":null,"access":{"kycMint":"unknown","kycSecondary":"unknown","kycRedeem":"unknown","accreditedOnly":false,"whitelistRequired":false},"verified":"imported","isin":null,"underlyingSymbol":null,"underlyingIsin":null,"lifecycle":"terminated","maturityDate":null,"contract":null,"targetArea":[],"areas":[],"_links":{"page":"https://tokenbank.world/token/RS-FIN","all":"https://tokenbank.world/api/tokens"},"_disclaimer":"Sourced figures; yields are variable and not guaranteed. Target/Area describe who the issuer aims the product at and where. They are not an eligibility check — who may buy is set by the issuer. Not investment advice. Verify the source before relying on any figure."}